Qube Research & Technologies (QRT)
NRIX icon

Qube Research & Technologies (QRT)’s Nurix Therapeutics NRIX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.6M Buy
449,161
+340,404
+313% +$8.49M 0.01% 1413
2026
Q2 		$2.64M Sell
108,757
-376,455
-78% -$6.41M ﹤0.01% 2005
2026
Q1 		$7.52M Buy
485,212
+459,223
+1,767% +$7.61M 0.01% 1455
2025
Q4 		$493K Sell
25,989
-690,546
-96% -$9.9M ﹤0.01% 2812
2025
Q3 		$6.62M Buy
716,535
+359,793
+101% +$3.74M 0.01% 1581
2025
Q2 		$4.06M Buy
356,742
+61,995
+21% +$670K ﹤0.01% 1832
2025
Q1 		$3.5M Sell
294,747
-58,724
-17% -$982K ﹤0.01% 1719
2024
Q4 		$6.66M Buy
353,471
+138,743
+65% +$3.18M 0.01% 1335
2024
Q3 		$4.82M Buy
214,728
+119,304
+125% +$2.7M 0.01% 1405
2024
Q2 		$1.99M Buy
+95,424
New +$1.49M ﹤0.01% 1628
2023
Q1 		– Sell
-11,179
Closed -$123K – 2870
2022
Q4 		$123K Buy
+11,179
New +$135K ﹤0.01% 1951
2022
Q2 		– Sell
-33,003
Closed -$462K – 2930
2022
Q1 		$462K Buy
+33,003
New +$586K ﹤0.01% 1570

Other funds holding NRIX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
General Atlantic
General Atlantic New York $2.48B AUM 19.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Qube Research & Technologies (QRT)'s NRIX Position: Q3 2026 in Review

Qube Research & Technologies (QRT) increased its Nurix Therapeutics (NRIX) stake by 313% in Q3 2026, buying an estimated $8.49M and bringing the position to 449,161 shares worth $10.6M. The position accounts for 0.01% of the portfolio, ranked #1413.

Qube Research & Technologies (QRT) first reported a position in NRIX in Q1 2022 and has held it in 12 quarters since. 157 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Qube Research & Technologies (QRT) held 449,161 shares of Nurix Therapeutics worth $10.6M as of Q3 2026.
  • Qube Research & Technologies (QRT) bought 340,404 Nurix Therapeutics shares in Q3 2026, an estimated $8.49M.
  • Nurix Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #1413 holding.
  • Qube Research & Technologies (QRT) first reported a position in Nurix Therapeutics in Q1 2022 and has held it in 12 quarters since.
  • 157 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.